Head-to-head · free
Lexeo Therapeutics, Inc. Common Stock vs MannKind
LXEO vs MNKD — return on capital, cash generation, margins and balance sheet side by side.
LXEO
1 / 3
measures where LXEO leads
MNKD
2 / 3
measures where MNKD leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | LXEO · FY2025 | MNKD · FY2025 |
|---|---|---|
| Revenue | — | $349.0M |
| Net income | (100.0M) | $5.9M |
| Revenue growth (yearly, multi-year) | — | 46.7% |
| Free cash flow | (99.0M) | $13.7M |
| Free cash flow margin | — | 3.9% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -55.0% | — |
| Gross margin | — | 74.8% |
| Operating margin | — | 13.3% |
| Net debt / EBITDA | 0.59x | 5.48x |
Figures are as reported by each company; latest fiscal year shown.
Where Lexeo Therapeutics, Inc. Common Stock's cash went (FY2025)
- Capital spending
- $397000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where MannKind's cash went (FY2025)
- Capital spending
- $4.6M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free